Search

Your search keyword '"Katane, M."' showing total 3 results
Start Over Author "Katane, M." Publisher elsevier b.v.
3 results on '"Katane, M."'

1. Cerebrospinal fluid and serum D-serine concentrations are unaltered across the whole clinical spectrum of Alzheimer's disease

Author

Nuzzo, T., Miroballo, M., Casamassa, A., Mancini, A., Gaetani, L., Nistico, R., Eusebi, P., Katane, M., Homma, H., Calabresi, Paolo, Errico, F., Parnetti, L., Usiello, A., Calabresi P. (ORCID:0000-0003-0326-5509), Nuzzo, T., Miroballo, M., Casamassa, A., Mancini, A., Gaetani, L., Nistico, R., Eusebi, P., Katane, M., Homma, H., Calabresi, Paolo, Errico, F., Parnetti, L., Usiello, A., and Calabresi P. (ORCID:0000-0003-0326-5509)

Abstract

The diagnosis of Alzheimer's disease (AD) relies on the presence of amyloidosis and tauopathy, as reflected in cerebrospinal fluid (CSF), independently from the clinical stage. Recently, CSF D-serine has been proposed as a possible new AD biomarker, reflecting dysfunctional activation of neuronal glutamatergic N-methyl-D-aspartate receptor (NMDAR). In this study, we measured blood serum and CSF concentration of two NMDAR modulators, such as D-serine and D-aspartate, in a cohort of drug-free subjects encompassing the whole AD clinical spectrum. In addition, we also analyzed D-serine levels in a cohort of post-mortem AD and control cortex samples. We reported unaltered serum and CSF concentrations of D-serine and D-aspartate in AD patients both during the AD progression and compared to non-demented controls. Accordingly, no correlation was detected between serum or CSF D-serine content and mini-mental state examination or Clinical Dementia Rating. Similarly, cortical D-serine levels were also unaltered in post-mortem samples of AD patients. Overall, our results failed to confirm previous findings indicating the CSF D-serine as a novel biomarker for AD.

Published
2020

3. Cerebrospinal fluid and serum D-serine concentrations are unaltered across the whole clinical spectrum of Alzheimer's disease

Author

Andrea Mancini, Lucilla Parnetti, Alessia Casamassa, Paolo Eusebi, Masumi Katane, Tommaso Nuzzo, Lorenzo Gaetani, Francesco Errico, Paolo Calabresi, Hiroshi Homma, Robert Nisticò, Mattia Miroballo, Alessandro Usiello, Nuzzo, T., Miroballo, M., Casamassa, A., Mancini, A., Gaetani, L., Nistico, R., Eusebi, P., Katane, M., Homma, H., Calabresi, P., Errico, F., Parnetti, L., Usiello, A., Nuzzo, T, Miroballo, M, Casamassa, A, Mancini, A, Gaetani, L, Nisticò, R, Eusebi, P, Katane, M, Homma, H, Calabresi, P, Errico, F, and Parnetti, L

Subjects
0301 basic medicine, Male, D-amino acid, Amyloid beta-Peptide, Biochemistry, Analytical Chemistry, 0302 clinical medicine, Cerebrospinal fluid, Blood serum, Serine, 80 and over, Receptor, Aged, 80 and over, Amyloidosis, Postpartum Period, Settore BIO/14, Brain, Alzheimer's disease, Prognosis, Settore MED/26 - NEUROLOGIA, Organ Specificity, Biomarker (medicine), D-amino acids, Female, Tauopathy, Human, medicine.medical_specialty, Prognosi, Clinical Dementia Rating, Biophysics, tau Proteins, 03 medical and health sciences, Biomarker, Dementia, Mild cognitive impairment, Alzheimer Disease, Internal medicine, medicine, Humans, Molecular Biology, Aged, Aspartic Acid, Amyloid beta-Peptides, business.industry, tau Protein, medicine.disease, 030104 developmental biology, Endocrinology, business, 030217 neurology & neurosurgery, Biomarkers
Abstract

The diagnosis of Alzheimer's disease (AD) relies on the presence of amyloidosis and tauopathy, as reflected in cerebrospinal fluid (CSF), independently from the clinical stage. Recently, CSF d-serine has been proposed as a possible new AD biomarker, reflecting dysfunctional activation of neuronal glutamatergic N-methyl-d-aspartate receptor (NMDAR). In this study, we measured blood serum and CSF concentration of two NMDAR modulators, such as d-serine and d-aspartate, in a cohort of drug-free subjects encompassing the whole AD clinical spectrum. In addition, we also analyzed d-serine levels in a cohort of post-mortem AD and control cortex samples. We reported unaltered serum and CSF concentrations of d-serine and d-aspartate in AD patients both during the AD progression and compared to non-demented controls. Accordingly, no correlation was detected between serum or CSF d-serine content and mini-mental state examination or Clinical Dementia Rating. Similarly, cortical d-serine levels were also unaltered in post-mortem samples of AD patients. Overall, our results failed to confirm previous findings indicating the CSF d-serine as a novel biomarker for AD.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results